# Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05800223/  
OnCo record `nct05800223` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of aumolertinib in lung cancer, run by Shanghai Cancer Hospital, China, now recruiting.

## Summary

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05800223 by Shanghai Cancer Hospital, China, with a registry enrolment figure of 300 participants, started 2023-01-01 and due to reach its primary completion in 2027-12. Interventions recorded: Almonertinib; SBRT. Conditions listed: Non-small Cell Lung Cancer Metastatic. Primary outcome: iPFS. Lung eligibility wording from the registry: "histologically confirmed NSCLC (by AJCC 8th edition lung cancer staging criteria)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05800223
- Phase: 3
- Setting: Prospective, Multicenter, Randomized Controlled, Phase III Clinical Study of Armatinib Alone or in Combination With Stereotactic Body Radiotherapy (SRT) for First-line Treatment of Brain Metastases From EGFR-mutated Non-small Cell Lung Cancer
- Sponsor: Shanghai Cancer Hospital, China
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT05800223: https://clinicaltrials.gov/study/NCT05800223

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05800223.json